Establishment and characterization of multidrug-resistant gastric cancer cell lines

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 915-922

  Zhang, Xiaotian ^a,b   Yashiro, Masakazu ^a   Qiu, Hong ^a,c   Nishii, Takafumi ^a   Matsuzaki, Taro ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Anticancer drugs; Apoptosis; Cell cycle; Chemotherapy; Cross resistance; Gastric cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DEATH ASSOCIATED PROTEIN KINASE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PACLITAXEL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CROSS RESISTANCE; DRUG EXPOSURE; GENE EXPRESSION; IC 50; MULTIDRUG RESISTANCE; OCUM 2M CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEINS; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 77951047269     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics, 2004. CA: a cancer journal for clinicians 54: 8-29, 2004.
2. Roth AD: Chemotherapy in gastric cancer: a never ending saga. Ann Oncol 14: 175-177, 2003. (Pubitemid 36312927)
3. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
4. Caponigro F, Facchini G, Nasti G and Iaffaioli RV: Gastric cancer. Treatment of advanced disease and new drugs. Front Biosci 10: 3122-3126, 2005.
5. Al-Batran SE, Jager E and Scholz M: Chemotherapy for advanced gastric cancer. J Clin Oncol 25: 729; author reply 730, 2007.
6. Cavanna L, Artioli F, Codignola C, Lazzaro A, Rizzi A, Gamboni A, Rota L, Rodino C, Boni F, Iop A and Zaniboni A: Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol 29: 371-375, 2006. (Pubitemid 44201990)
7. Beretta E, Di Bartolomeo M, Buzzoni R, Ferrario E, Mariani L, Gevorgyan A and Bajetta E: Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition. Tumori 92: 379-383, 2006. (Pubitemid 44867398)
8. Correale P, Fulfaro F, Marsili S, Cicero G, Bajardi E, Intrivici C, Vuolo G, Carli AF, Caraglia M, Del Prete S, Greco E, Gebbia N and Francini G: Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. Cancer Chemother Pharmacol 56: 563-568, 2005. (Pubitemid 41430301)
9. Ohi S, Takahashi N, Ninomiya K, Nakajima M, Hashimoto H, Tachibana T, Yanaga K and Ishikawa H: Establishment and characterization of a cisplatin-resistant cell line (IGSK-1) from a poorly differentiated gastric adenocarcinoma. Hum Cell 20: 15-22, 2007. (Pubitemid 46761471)
10. Chung YM, Park S, Park JK, Kim Y, Kang Y and Yoo YD: Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 159: 95-101, 2000. (Pubitemid 30421224)
11. Yashiro M, Chung YS, Nishimura S, Inoue T and Sowa M: Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Br J Cancer 72: 1200-1210, 1995.
12. Nitta A, Chung YS, Nakata B, Yashiro M, Onoda N, Maeda K, Sawada T and Sowa M: Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M/DDP. Cancer Chemother Pharmacol 40: 94-97, 1997. (Pubitemid 27160968)
13. Pollera CF, Ceribelli A, Crecco M and Calabresi F: Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study. Invest New Drugs 12: 111-119, 1994.
14. Donaldson KL, Goolsby GL and Wahl AF: Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. International journal of cancer 57: 847-855, 1994.
15. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
16. Ackland SP and Peters GJ: Thymidine Phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resist Updat 2: 205-214, 1999.
17. Fischel JL, Etienne MC, Spector T, Formento P, Renee N and Milano G: Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin Cancer Res 1: 991-996, 1995.
18. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J and Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182, 1996. (Pubitemid 26020011)
19. Kogel D, Prehn JH and Scheidtmann KH: The DAP kinase family of pro-apoptotic proteins: novel players in the apoptotic game. Bioessays 23: 352-358, 2001. (Pubitemid 32285760)